Triglav Investments D.O.O. Decreases Stake in AstraZeneca PLC $AZN

Triglav Investments D.O.O. decreased its position in AstraZeneca PLC (NASDAQ:AZN) by 1.3% in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 88,982 shares of the company’s stock after selling 1,154 shares during the period. Triglav Investments D.O.O.’s holdings in AstraZeneca were worth $6,217,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Lindbrook Capital LLC increased its stake in AstraZeneca by 1.9% in the 1st quarter. Lindbrook Capital LLC now owns 7,574 shares of the company’s stock valued at $557,000 after buying an additional 141 shares during the last quarter. Principal Securities Inc. increased its stake in AstraZeneca by 0.5% in the 1st quarter. Principal Securities Inc. now owns 28,053 shares of the company’s stock valued at $2,062,000 after buying an additional 142 shares during the last quarter. Sage Mountain Advisors LLC grew its position in shares of AstraZeneca by 3.4% during the 1st quarter. Sage Mountain Advisors LLC now owns 4,478 shares of the company’s stock valued at $329,000 after acquiring an additional 147 shares during the period. Richardson Financial Services Inc. grew its position in shares of AstraZeneca by 59.8% during the 2nd quarter. Richardson Financial Services Inc. now owns 398 shares of the company’s stock valued at $28,000 after acquiring an additional 149 shares during the period. Finally, Evergreen Capital Management LLC grew its position in shares of AstraZeneca by 0.7% during the 1st quarter. Evergreen Capital Management LLC now owns 23,709 shares of the company’s stock valued at $1,743,000 after acquiring an additional 155 shares during the period. Hedge funds and other institutional investors own 20.35% of the company’s stock.

AstraZeneca Stock Up 0.1%

AZN opened at $82.40 on Friday. The company has a 50 day moving average of $81.13 and a 200 day moving average of $75.02. The company has a market cap of $255.56 billion, a PE ratio of 30.98, a price-to-earnings-growth ratio of 1.52 and a beta of 0.36. AstraZeneca PLC has a 12 month low of $61.24 and a 12 month high of $86.57. The company has a current ratio of 0.86, a quick ratio of 0.67 and a debt-to-equity ratio of 0.55.

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on the stock. Deutsche Bank Aktiengesellschaft downgraded shares of AstraZeneca from a “hold” rating to a “sell” rating in a research report on Thursday, October 16th. Berenberg Bank set a $97.00 target price on shares of AstraZeneca in a research report on Wednesday, July 9th. Jefferies Financial Group assumed coverage on shares of AstraZeneca in a research report on Monday, October 27th. They set a “buy” rating for the company. Finally, Weiss Ratings reissued a “buy (b)” rating on shares of AstraZeneca in a research report on Wednesday, October 8th. Five analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $86.00.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.